/C O R R E C T I O N — CSL Biotherapies, Inc./
In the news release, CSL Biotherapies initiates shipments of its seasonal influenza vaccine to U.S. customers, issued
CSL Biotherapies initiates shipments of its seasonal influenza vaccine to U.S. customers
Approximately 11 million doses to be delivered within 2 months
KING OF PRUSSIA, Pa., Aug. 6, 2013 /PRNewswire/ – CSL Biotherapies, Inc. announced today that shipment of its seasonal influenza vaccine for the 2013-2014 season has started.
“Given the magnitude of influenza burden in the U.S. and the unpredictability of seasonal outbreaks, timely delivery of flu vaccines is more critical now than ever before,” said Dr. Marie Mazur, Head of Worldwide Commercial Operations, Influenza. “CSL Biotherapies is committed to addressing this public health need by consistently delivering its influenza vaccine early to the healthcare providers in the United States.”
CSL Biotherapies will ship approximately 11 million doses of the seasonal flu vaccine to the United States for the upcoming season. Shipment will comprise multi-dose and pre-filled syringe presentations.
About CSL Biotherapies, Inc.
CSL Biotherapies, Inc., located in King of Prussia, PA, is the U.S. headquarters of bioCSL. Parent company CSL Limited has manufactured influenza vaccine in its Melbourne, Australia facility since 1968. CSL Limited has made a $60 million (U.S.D.) investment in plant and equipment to double capacity at its Melbourne facility, making it one of the largest vaccine manufacturing facilities in the world. CSL-branded influenza vaccines are approved in 28 countries.
At bioCSL, delivering vaccines is our mission, protecting lives our passion. The CSL Group, which also includes CSL Research & Development, CSL Plasma, and CSL Behring, has more than 11,000 employees globally and operates in 26 countries around the world.
SOURCE CSL Biotherapies, Inc.